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Abstract 
An important aspect of the management of patients with endometrial cancer (ER) is the 
timely identification of risk groups, early signs of the onset and recurrence of the disease. There 
is an active search for new markers for early diagnosis, detection of relapses and postoperative 
monitoring of RE. Tumor necrosis factor alpha (TNFα) is a cytokine involved in the 
pathogenesis of various forms of cancer, as well as associated with chronic inflammation, 
obesity. The goal is to study the methylation of the TNFa gene in the OM and the possibility of 
using it as a marker for forecasting, monitoring, and the risk of developing the OM. Materials 
and methods. DNA methylation was determined by the method of pyrosequencing in 
endometrial specimens taken from 10 patients with verified endometrial hyperplasia and 13 
patients with RE when performing hysteroscopy with endometrial biopsy or endometrial 
curettage. Results and discussion. The total degree of methylation of the TNFα gene DNA 
promoter in the samples under study in patients with simple and / or complex nonatypical 
endometrial hyperplasia was 62.6 ± 12.8% and was higher than in RE patients (34.7 ± 8.8%). 
Findings. The results of the study showed the involvement of the epigenetic mechanism, which 
is associated with hypomethylation of the TNFα gene promoter, which can lead to the activation 
of the TNFα gene in RE. Determining the amount of methylation DNA promoter of the TNFα 
gene can be used as a potential prognostic and diagnostic marker for ER. 
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Introduction 
Endometrial cancer (ER) is one of the first places among cancer diseases of the female 
genital. Treatment of ER often includes surgical, radiotherapy and chemotherapeutic methods, 
which require constant monitoring of effectiveness to control. An important aspect of the 
management of patients with ER is the timely identification of risk groups, early signs of the 
onset and recurrence of the disease. Currently used proteomic tumor-associated markers detected 
using the method of enzyme immunoassay - cancer antigen 125 (CA125) and human epididymis 
protein 4 (HE4). With a high level of sensitivity, CA125 has a low level of specificity regarding 
tumor localization. HE4 is a tumor marker that has a higher sensitivity and specificity for the 
diagnosis of tumors of the pelvic organs compared to CA125. It should be noted that the 
diagnostic capabilities of both markers, HE4 and CA125, are limited [1]. Therefore, an active 
search for new markers for early diagnosis, detection of relapses and postoperative monitoring of 
ER is currently underway. It has been proven that many forms of tumor transformation are 
associated with chronic inflammation, obesity, and diabetes. Cytokines have attracted keen 
attention of researchers, which is associated with their participation in the pathogenesis of 
various forms of cancer [2]. One such cytokine is tumor necrosis factor alpha (TNFα), associated 
with chronic inflammation, obesity and cancer. 
TNF can play a dual role in tumor biology. It is a cytokine with well-known anti-cancer 
properties, which can also contribute to the development and progression of cancer [3]. The 
literature describes that in patients with a diagnosis of lung cancer in the TNF network 
hypomethylated The literature describes that patients with a diagnosis of lung cancer in the TNF 
network hypomethylated genes were cytokines CCL3, CCL4, CCL7, CCL8, CCL22, IL21, 
IL17A, EBI3, which can either stimulate or inhibit the growth and progression of the tumor [4]. 
Preservation of high expression of TNFα and proinflammatory cytokines leads to tissue damage 
in the inflammatory focus, including by stimulating the production of metalloproteinases. In 
addition, TNFα is involved in the regulation of the proapoptotic Bcl2 gene. The involvement of 
TNFα in the regulation of various cellular pathways makes it a significant target for studying it 
as a marker for diagnosis, prognosis and a possible target for the therapy of RE. 
Objective: to study the methylation of the TNFa gene in the OM and the possibility of 
using it as a marker for forecasting, monitoring, and the risk of developing the OM. 
 
Materials and methods 
For the study, endometrial samples were taken from the surgical material of 13 patients 
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(42–79 years old) with a morphologically established diagnosis of RE, as well as uterine mucosa 
with simple and / or complex nonatypical endometrial hyperplasia of 10 women (age 27-43 
years). 
The women included in the study were admitted in a planned or urgent manner to the 
gynecological department of the Multidisciplinary Medical Center (University Clinic No. 1) of 
the Odessa National Medical University for performing hysteroscopy with targeted biopsy, 
resection of the endometrium (if indicated) or fractional treatment-diagnostic curettage of the 
walls of the uterus. Indications for treatment and diagnostic operations in patients with simple 
and / or complex endometrial hyperplasia, ER: abnormal uterine bleeding, endometrial 
hyperproliferative process according to the results of ultrasound examination of the pelvic organs 
(in order to clarify the pathological diagnosis). 
To study the methylation of the TNFα gene in patients with RE and patients with simple 
and / or complex non-typical hyperplasia of the endometrium, DNA from tissue samples was 
isolated using the QIAamp DNA Mini Kit (Qiagen). The DNA concentration was determined 
spectrophotometrically on a NanoDrop spectrophotometer and adjusted to a concentration of 1 
μg / ml in all samples. Bisulfite treatment of the isolated DNA was performed using the EpiTect 
Plus Bisulfite Kits kit (Qiagen). DNA amplification was performed using the HotStarTaq DNA 
Polymerase kit (Qiagen) according to the program (Table 1): 950С - 15 min; 950С - 30 sec, 
annealing of primers 52 0С - 30 sec, elongation 720С - 10 min. Pyrosequencing was performed 
using PyroMark Gold Q24 reagent kits (Qiagen) on a PyroMark Q24 instrument in the 
laboratory of molecular pathology of the Institute of Pathology (Erlangen, Germany). The 
content of methylated DNA in the sample was evaluated using the PyroMark CpG software 2.01 
program. Statistical data processing was performed using the program Statistica, Versia 10. 
 
Table 1. Primers for DNA methylation analysis of the TNFα gene 
Gene name  Primer  Т, 0С 
TNFα F-[Biotin]GAGTGTGAGGGGTATTTTTGATG  52 
TNFα R-GCAACCATAATAAACCCTACACCTTC  
TNFα Seq-AAACCCTACACCTTCTATCT LINE1 
 
Results and discussion 
In the study, the DNA methylation of the TNFα gene promoter was studied in 13 patients 
with RE and 10 women diagnosed with simple and / or complex nonatypical endometrial 
hyperplasia. Four methylation sites in the proximal promoter of the TNFα gene were analyzed. 
The results of the study showed that the total degree of methylation of the promoter of the 
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TNFα gene in the samples under study in patients with simple and / or complex nonatypical 
endometrial hyperplasia was 62.6 ± 12.8% and was higher than in patients with RE, in which this 
indicator was 34.7 ± 8.8% (Fig. 1). That is, in the endometrial tissue with simple and / or 
complex non-atypical hyperplasia, the content of methylated DNA of the TNFα gene is 62.6%. 
In the group of patients suffering from ER - 34.7%. The decrease in the content of methylated 
DNA of the TNFα gene promoter in RE samples compared with samples of simple and complex 
nonatypical endometrial hyperplasia was significantly, p≤0.01. 
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Fig. 1. DNA methylation of the TNFα gene promoter in re-tissue samples and simple and 
/ or complex nonatypical endometrial hyperplasia. 
 
Reducing DNA methylation of the TNFα gene promoter leads to an increase in TNFα 
expression in endometrial tissue and may contribute to the manifestation of various direct and 
mediated cellular effects associated with the participation of TNFα in the regulatory pathways 
responsible for proliferation, apoptosis, proinflammatory and cytotoxic effects. 
TNFα is a key cytokine of the immune system, which initiates and stimulates 
inflammation, which in certain conditions can lead to the development of chronic inflammatory 
diseases and uncontrolled cell growth. Activation of the NFκB pathway in epithelial cells, 
macrophages, neutrophils is a key effect of TNF, leading, on the one hand, to increased 
production of pro-inflammatory cytokines, and, on the other hand, to the production of iNOS, 
COX-2 and NOX subunits, thereby activating NADPH oxidase, which leads to the production of 
reactive oxygen species (ROS). As already known, free hydroxyl superoxide radicals can 
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contribute to DNA and RNA damage, oxidize enzymes, proteins, cell membrane lipids, increase 
cell proliferation, thereby contributing to the growth and progression of the tumor. 
 
Findings 
The results of the study showed the involvement of the epigenetic mechanism, which is 
associated with hypomethylation of the TNFα gene promoter, which can lead to the activation of 
the TNFα gene in RE. Determining the amount of methylation DNA promoter of the TNFα gene 
can be used as a potential prognostic and diagnostic marker for ER. 
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